On August 28, 2026, anal wellness brand Future Method began selling three physician-developed products in more than 800 CVS stores nationwide — the $39.99 2-Piece Silicone Anal Beginner Dilator Set, the $26.99 2-Pack Single-Use Anal Douche Kit and the $26.99 Reusable Anal Douche Kit — placed in the chain's sexual wellness sections. The brand was founded by Dr. Evan Goldstein, the anal surgeon who owns Manhattan practice Bespoke Surgical, and the dilator set was designed specifically for the CVS rollout as an entry-level SKU. The move follows Future Method's recent arrival on Walmart Marketplace.

Why It Matters

Mass-retail sexual wellness has had a rocky few years. The pandemic-era wave that put Dame, Bloomi, Cake and Jems on drugstore shelves alongside Durex lost momentum amid consumer caution, e-commerce discretion and the sheer difficulty of building awareness for unproven brands. Future Method landing at CVS signals that the next phase of mainstreaming is narrower and more clinical: not general-purpose "intimacy" brands, but specific, doctor-backed solutions for categories retailers previously wouldn't touch. It also puts explicitly queer-coded sexual health products in a national pharmacy chain that already dispenses PrEP and DoxyPEP — an integration play that matters more for category legitimacy than for first-year revenue. For competitors, the tell is Goldstein's decision to take 800 doors instead of 9,000: distribution is no longer the scarce resource in sexual wellness, sell-through is.

Notably, Goldstein turned down a bigger doorcount. Beauty Independent reported that CVS wanted Future Method across its roughly 9,000-store U.S. fleet, but Goldstein opted for a targeted first wave concentrated in college towns and urban centers — high-demand markets where a young brand can prove sell-through before committing to national replenishment. It is a rare instance of a small sexual wellness brand pumping the brakes on mass distribution rather than chasing it.

The merchandising problem Future Method is trying to solve is a structural one. In a typical drugstore planogram, enemas sit in the constipation aisle, several aisles away from lubricants and condoms in sexual wellness — meaning the shopper prepping for anal sex and the shopper managing digestive symptoms are sent to entirely different parts of the store for functionally adjacent products. Future Method and CVS are exploring cross-aisle placement plus pharmacist training. "People are going there for PrEP, they're going there for DoxyPEP," Goldstein told Beauty Independent, arguing pharmacists should be equipped to ask "what are you using to clean out, and are you using stuff with preservatives because that is a problem."

The clinical pitch is the differentiator. Goldstein argues that many conventional liquid enemas and cleansing douches contain preservatives, or carry an osmolality that can disrupt the rectal mucosal lining and potentially raise STI vulnerability. Future Method's kits instead use powder-based, isotonic formulations reconstituted with tap water, which eliminates the need for synthetic preservatives. That framing — risk reduction rather than pleasure — is also how the brand gets shelf space in the first place. "I wouldn't even talk about anal in this space," Goldstein said. "I would just talk about risk reduction for sexual practices."

Speaking to Out, Goldstein framed CVS as "the first retailer to go full spectrum," pairing pharmacy-counter access to PrEP, DoxyPEP and Valtrex with aisle-level anal wellness products, and called the launch "a major milestone" while adding that the category still lacks "the visibility, research, and investment it deserves."

Sources

Update — 2026-08-30

{Initial entry — story first created.}